AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32105820
Drug: Prostaglandin F2α
RxNorm normalized name: 15(S)-15-Methyl Prostaglandin F2α
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin F2α (PGF2α) injection into the cervix before and after surgery
Trial: 32105820
Drug: Prostaglandin F2α
RxNorm normalized name: 15(S)-15-Methyl Prostaglandin F2α
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin F2α (PGF2α) injection
Trial: 32105820
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no PGF2α injection)
Trial: 35157055
Drug: Icosapent ethyl
RxNorm normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Icosapent ethyl (IPE), 4 g/d
Trial: 35802375
Drug: 195-mg transdermal
RxNorm normalized name: levodopa 195 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 195-mg transdermal cannabidiol
Trial: 35802375
Drug: 390-mg transdermal
RxNorm normalized name: guaifenesin 390 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 390-mg transdermal cannabidiol
Trial: 35802375
Drug: Cannabidiol (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabidiol (combined 195-mg and 390-mg)
Trial: 34587373
Drug: Individualized BP-lowering
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized BP-lowering treatment
Trial: 34587373
Drug: Standard BP-lowering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard BP-lowering treatment
Trial: 33601858
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg once daily for 5 days along with general supportive treatment
Trial: 32524129
Drug: Dynamic enteral
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic enteral and parenteral nutrition support with ω‐3 fish oil fat milk injection and glutamine
Trial: 32524129
Drug: Routine postoperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine postoperative enteral and parenteral camp support
Trial: 32524129
Drug: Dynamic enteral
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic enteral and parenteral nutrition support
Trial: 35584865
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (1.2 mg/kg), doxorubicin (25 mg/m2), vinblastine (6 mg/m2), dacarbazine (375 mg/m2), and rituximab (375 mg/m2) for four or six cycles.
Trial: 35584865
Drug: Brentuximab vedotin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brentuximab vedotin, rituximab, and risk-adapted chemotherapy.
Trial: 39315334
Drug: Bivalent HPV
RxNorm normalized name: HPV, bivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent HPV vaccine
Trial: 35926984
Drug: Intra-arterial thrombolytics
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial thrombolytics (urokinase median dose 250,000 IU, alteplase median dose 20 mg)
Trial: 32191400
Drug: UDCA 300
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA 300 mg twice daily
Trial: 32191400
Drug: UDCA 300
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA 300 mg twice daily for 4 weeks followed by UDCA 300 mg twice daily and metformin 500 mg twice daily for 4 weeks
Trial: 36205206
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (hydroxychloroquine)
Trial: 32546269
Drug: Short-course antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course antibiotic therapy for 2 weeks
Trial: 32546269
Drug: Conventional antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antibiotic therapy (4-6 weeks)
Trial: 35871815
Drug: Single intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intramuscular glucocorticoid injection (120 mg) and a 1‐year course of oral methotrexate (up to 25 mg/week)
Trial: 35871815
Drug: Placebo (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (single injection and tablets for 1 year)
Trial: 35604466
Drug: Language therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Language therapy (control group)
Trial: 35984159
Drug: Empirical concomitant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical concomitant therapy (CoT): rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg twice daily for 14 days
Trial: 35984159
Drug: Tailored therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored therapy (TaT): rabeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg twice daily for 14 days for point mutation-negative patients; rabeprazole 20 mg twice daily, metronidazole 500 mg thrice daily, bismuth 120 mg, and tetracycline 500 mg 4 times daily for 14 days for point mutation-positive patients
Trial: 35984159
Drug: Empirical concomitant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical concomitant therapy (CoT) in point mutation-positive patients
Trial: 35984159
Drug: Tailored therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored therapy (TaT) in point mutation-positive patients
Trial: 35466156
Drug: High-dose pitavastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pitavastatin (4 mg/day × 4 days)
Trial: 35510343
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health promotion intervention (individual support to improve oral health)
Trial: 34541982
Drug: PRIME needle-free
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRIME needle-free injection system
Trial: 35809825
Drug: Vaccine with
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine with 90% efficacy
Trial: 33684506
Drug: sucrose (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sucrose (80 g/day)
Trial: 33684506
Drug: fructose (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fructose (80 g/day)
Trial: 33684506
Drug: glucose (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glucose (80 g/day)
Trial: 32080148
Drug: traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: traditional treatment + intravenous infusion of edaravone 30 mg twice a day for 14 days
Trial: 35255966
Drug: MenSC-derived secretome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenSC-derived secretome treatment (5 mL intravenous infusions for five days)
Trial: 35255966
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo, 5 mL intravenous infusions for five days)
Trial: 35255966
Drug: MenSC-derived secretome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenSC-derived secretome treatment
Trial: 34837169
Drug: Palbociclib test
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib test formulation (125 mg) under fasting condition
Trial: 34837169
Drug: Palbociclib test
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib test formulation (125 mg) under fed condition
Trial: 34837169
Drug: Palbociclib reference
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib reference formulation (125 mg) under fasting condition
Trial: 34837169
Drug: Palbociclib reference
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib reference formulation (125 mg) under fed condition
Trial: 32808029
Drug: L-cysteine (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-cysteine (1200 mg)
Trial: 32808029
Drug: L-cysteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-cysteine (600 mg)
Trial: 35895764
Drug: BLS (bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLS (bupivacaine liposomal suspension)
Trial: 32789530
Drug: Bag-of-features (BOF)
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bag-of-features (BOF) features with augmentation from contrast-enhanced MRI (CE-MRI)
Trial: 32493383
Drug: Modified Diagnostic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Diagnostic Strategy (MODS) with D-dimer threshold raised to 1000 ng/ml if no items of the YEARS score are present.
Trial: 32493383
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care with D-dimer threshold of 500 ng/ml for patients aged 50 years or younger and age × 10 for older patients.
Trial: 35293783
Drug: Erythromycin 400
RxNorm normalized name: ERYTHROMYCIN 400 mg in 5.2 g TOPICAL POWDER [API E.M ERYTHROMYCIN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 400 mg twice daily for 4 weeks
Trial: 35293783
Drug: Azithromycin 125
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 125 mg twice daily for 4 weeks
Trial: 32910863
Drug: Cytoflavin antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin antioxidant energy therapy
Trial: 33789267
Drug: Intratympanic triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic triamcinolone acetonide injections (up to 3 injections at 1-week intervals)
Trial: 33789267
Drug: Intratympanic triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic triamcinolone acetonide injections
Trial: 34192419
Drug: BAY 2433334
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 2433334 (5–150 mg as oral solution or immediate-release tablets)
Trial: 34192419
Drug: BAY 2433334
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 2433334 (5 mg tablets) with a high-calorie breakfast
Trial: 32971450
Drug: Chromium picolinate
RxNorm normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chromium picolinate (500 μg/day)
Trial: 35748058
Drug: YH4808 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH4808 at 30, 50, 100, 200, 400, 600, and 800 mg (single oral dose)
Trial: 35748058
Drug: YH4808 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH4808 at 100, 200, and 400 mg (multiple once-daily oral doses for 7 days)
Trial: 35748058
Drug: Omeprazole at
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole at 40 mg (active comparator)
Trial: 35748058
Drug: YH4808 (repeated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH4808 (repeated doses)
Trial: 32371537
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with trastuzumab-containing regimens
Trial: 33728848
Drug: ipidacrine added
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ipidacrine added to traditional therapy (n=50)
Trial: 33728848
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (n=42)
Trial: 34818363
Drug: Yokukansan (YKS),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yokukansan (YKS), 2.5 g doses before sleeping on the night before surgery and 2 hours before anesthesia induction
Trial: 34818363
Drug: Control (CNT),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (CNT), no medication preoperatively
Trial: 35500960
Drug: Routine physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine physical therapy along with Low Intensity Pulsed Ultrasound (LIPUS)
Trial: 35500960
Drug: Routine physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine physical therapy (Control Group)
Trial: 35565110
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment group (DTG, waiting list control)
Trial: 35491682
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac (IVK) administered pre-operatively
Trial: 35491682
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac (IVK) administered intra-operatively
Trial: 35491682
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac (IVK) administered post-operatively
Trial: 35709509
Drug: CBL-514 injection
RxNorm normalized name: OH-Cbl
DrugBank: Hydroxocobalamin (DB00200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CBL-514 injection at a dose of 2.0 mg/cm2 (300 mg)
Trial: 35709509
Drug: CBL-514 injection
RxNorm normalized name: OH-Cbl
DrugBank: Hydroxocobalamin (DB00200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CBL-514 injection at a dose of 1.6 mg/cm2 (240 mg)
Trial: 35709509
Drug: CBL-514 injection
RxNorm normalized name: OH-Cbl
DrugBank: Hydroxocobalamin (DB00200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CBL-514 injection at a dose of 1.2 mg/cm2 (180 mg)
Trial: 33470152
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulation restarted after 1 week
Trial: 33470152
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulation restarted after 2 weeks
Trial: 33470152
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulation restarted after 4 weeks
Trial: 34651171
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) hydration
Trial: 34651171
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) hydration
Trial: 35264347
Drug: TUS-guided pigtail
RxNorm normalized name: Tu Mu Xiang
DrugBank: Inula helenium root (DB14350)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TUS-guided pigtail catheter placement and intrapleural therapy with Actilyse and DNase
Trial: 36130946
Drug: Neflamapimod 40
RxNorm normalized name: Neflamapimod
DrugBank: Neflamapimod (DB07138)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neflamapimod 40 mg
Trial: 35063281
Drug: Paclitaxel 80mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel 80mg/m2 weekly up to 24 weeks (control)
Trial: 35063281
Drug: Olaparib 300mg
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300mg tablets twice daily + Cediranib 20mg daily (continuous schedule)
Trial: 35063281
Drug: Olaparib 300mg
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300mg tablets twice daily + Cediranib 20mg 5 days/week (intermittent schedule)
Trial: 35358464
Drug: Isatuximab plus
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Isatuximab plus pomalidomide and low-dose dexamethasone
Trial: 35151415
Drug: Pomalidomide and
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide and low-dose dexamethasone (Control)
Trial: 34506761
Drug: Cyclophosphamide (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (600 mg/m2) plus uromitexan (200 mg/m2) at days 0, 15, 30, and 60
Trial: 35940560
Drug: Topical tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid (TXA) 3g administered intra-articular after cementation and prior to capsular closure
Trial: 35075022
Drug: Single-shot caudal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-shot caudal morphine
Trial: 35075022
Drug: Intravenous narcotic-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous narcotic-based anesthesia
Trial: 34454540
Drug: Oral azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral azacitidine 300 mg once-daily for 14 days in repeated 28-day cycles
Trial: 34454540
Drug: Oral azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral azacitidine
Trial: 36896702
Drug: HPV-16/18 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV-16/18 vaccine
Trial: 35105495
Drug: HBV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV vaccine
Trial: 36326299
Drug: Sour cherry
RxNorm normalized name: SOUR CHERRY
DrugBank: Sour cherry (DB10630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sour cherry concentrate (75 ml twice daily for 2 weeks)
Trial: 32681461
Drug: ASP3652 (1–600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP3652 (1–600 mg single dose)
Trial: 32681461
Drug: ASP3652 (10–300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP3652 (10–300 mg bid and 600 mg qd for 14 days)
Trial: 32681461
Drug: ASP3652 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP3652 (single and multiple doses)
Trial: 32681461
Drug: ASP3652 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP3652 (multiple doses)
Trial: 32681461
Drug: ASP3652 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP3652 (single dose with food)
Trial: 35674613
Drug: T. harzianum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T. harzianum with 50 g of NPK treatment (T2)
Trial: 35674613
Drug: B. thuringiensis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B. thuringiensis plus 50 g NPK treatment (T3)
Trial: 35674613
Drug: B. thuringiensis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B. thuringiensis with 25 g NPK fertilizer treatment (T5)
Trial: 35333363
Drug: Attainment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attainment of multiple treatment targets
Trial: 33908296
Drug: 250 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 µg roflumilast
Trial: 33908296
Drug: 100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µg roflumilast
Trial: 35766037
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of candesartan and carvedilol plus standard of care
Trial: 35988057
Drug: EPI-589 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPI-589 (500 mg twice daily)
Trial: 35988057
Drug: EPI-589 (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPI-589 (750 mg twice daily)
Trial: 35988057
Drug: EPI-589 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPI-589 (1000 mg single daily dose)
Trial: 35988057
Drug: EPI-589 (250-1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPI-589 (250-1000 mg single doses)
Trial: 34742669
Drug: Group Intervention
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Intervention in OBEsity (IGOBE) program with weekly sessions for six weeks
Trial: 34742669
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care therapy (Control Group)
Trial: 34550930
Drug: Subglandular breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subglandular breast augmentation
Trial: 32736592
Drug: EDP1815 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP1815 (2 capsules twice daily for up to 7 days, with an option to extend to 14 days)
Trial: 32736592
Drug: Dapagliflozin (10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (10mg once daily) and Ambrisentan (5mg once daily for up to 14 days)
Trial: 35385557
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (ITM) 0.2 mg before general anesthesia
Trial: 33108123
Drug: Jiawei Xiaoyao
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jiawei Xiaoyao (JX) pill (12 g/d, 6 g twice a day) for 4 weeks
Trial: 33108123
Drug: Placebo (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (12 g/d, 6 g twice a day) for 4 weeks
Trial: 33108123
Drug: Jiawei Xiaoyao
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jiawei Xiaoyao (JX) pill
Trial: 34753557
Drug: RAS blockers
RxNorm normalized name: RAS
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RAS blockers (monotherapy or dual blockade)
Trial: 34753557
Drug: Baseline IL-6
RxNorm normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline IL-6 levels > 4.84 pg/mL
Trial: 34753557
Drug: RAS blockade
RxNorm normalized name: RAS
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RAS blockade (monotherapy or dual blockade)